Collaboration to focus on personalized medicine in the United Arab Emirates capital.
The Department of Health – Abu Dhabi, the governing board of healthcare in the United Arab Emirates (UAE), announced an agreement with AbbVie Biopharmaceutical and M42, an integrated healthcare company, in an effort to mold personalized medicine genomics within the city. As part of the partnership, the three parties intend to advance the diagnosis and treatment of multiple myeloma and non-small cell lung cancer.
"This partnership aims to advance precision medicine in the diagnosis and treatment to help enable broader patient access in UAE to innovative therapies,” said Hassan Sabbah, general manager, AbbVie Gulf & Levant. “Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges, and burdens."
Reference: Department of Health - Abu Dhabi, M42 and AbbVie enter a strategic partnership to advance personalised medicine and genomics. June 19, 2023. Accessed June 21, 2023. https://www.prnewswire.com/news-releases/department-of-health--abu-dhabi-m42-and-abbvie-enter-a-strategic-partnership-to-advance-personalised-medicine-and-genomics-301854543.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.